What is the study about?

The POISE trial aims to find out what is the most effective hormone treatment for women with premature ovarian insufficiency (POI), in both the short and long-term. The cause of POI is often unknown, but in some women, it may be caused by genetic conditions such as Turner's syndrome, as well as immune disorders, treatments for cancer, or surgery involving the ovaries.

Who can take part in the study?

Women aged ≥18 years to ≤ 40 years at time of randomisation and have a diagnosis of premature ovarian insufficiency (POI)

What is being tested in the study?

• Hormone replacement therapy (HRT) 
• Combined oral contraceptive pill (COC)

What is this being compared to?

See above – both offered as standard treatment on the NHS.

What are we trying to find out?

The primary outcome is the absolute bone mineral density (BMD)(g/cm) at 2 years from the date of randomisation, assessed by a standard dual energy X-ray absorptiometry (DEVA) scan, of the lumbar spine. 

How many patients do we need?

480 women

Funder

National Institute for Health and Care Research - Health Technology Assessment (NIHR - HTA)

Useful links